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Background-—The choice of optimal drug-eluting stent therapy for patients with diabetes mellitus (DM) undergoing percutaneous
coronary intervention remains uncertain. We aimed to assess the long-term clinical outcomes after percutaneous coronary
intervention with biodegradable polymer sirolimus-eluting stents (BP-SES) versus durable polymer everolimus-eluting stents (DP-
EES) in patients with DM.
Methods and Results-—In a prespeciﬁed subgroup analysis of the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer Sirolimus-
Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization) trial (NCT01443104),
patients randomly assigned to ultrathin-strut BP-SES or thin-strut DP-EES were stratiﬁed according to diabetic status. The primary
end point was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target
lesion revascularization, at 5 years. Among 2119 patients, 486 (22.9%) presented with DM. Compared with individuals without DM,
patients with DM were older and had a greater baseline cardiac risk proﬁle. In patients with DM, target lesion failure at 5 years
occurred in 74 patients (cumulative incidence, 31.0%) treated with BP-SES and 57 patients (25.8%) treated with DP-EES (risk ratio,
1.23; 95% CI, 0.87–1.73 [P=0.24]). In individuals without DM, target lesion failure at 5 years occurred in 124 patients (16.8%)
treated with BP-SES and 132 patients (16.8%) treated with DP-EES (risk ratio, 0.98; 95% CI, 0.77–1.26 [P=0.90; P for
interaction=0.31]). Cumulative 5-year incidence rates of cardiac death, target vessel myocardial infarction, clinically indicated
target lesion revascularization, and deﬁnite stent thrombosis were similar among patients with DM treated with BP-SES or DP-EES.
There was no interaction between diabetic status and treatment effect of BP-SES versus DP-EES.
Conclusions-—In a prespeciﬁed subgroup analysis of the BIOSCIENCE trial, we found no difference in clinical outcomes throughout
5 years between patients with DM treated with ultrathin-strut BP-SES or thin-strut DP-EES.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT01443104. ( J Am Heart Assoc. 2019;8:
e013607. DOI: 10.1161/JAHA.119.013607.)
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Among patients undergoing percutaneous coronary inter-vention (PCI), patients with diabetes mellitus (DM)
represent a high-risk subset compared with individuals
without DM and are at increased long-term risk of death,
myocardial infarction (MI), and repeat revascularization.1–3
Newer-generation drug-eluting stents (DES) are currently
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recommended for treatment of patients with DM undergoing
PCI owing to a lower risk of repeat revascularization
compared with bare-metal stents and early-generation thick-
strut permanent polymer-based DES.4 Among contemporary
available DES, thin-strut durable polymer everolimus-eluting
stents (DP-EES) were shown to provide the best safety and
efﬁcacy proﬁle in patients with DM.5 However, long-term
persistence of durable polymer coatings has been associated
with delayed vascular healing attributed to a chronic inﬂam-
matory process,6 translating into a persisting risk of late
adverse clinical events.7
Biodegradable polymer DES (BP-DES) were introduced with
the purpose of controlling antiproliferative drug release while
allowing subsequent polymer degradation, thus potentially
eliminating triggers of a chronic inﬂammatory tissue response
induced by durable polymer coatings and restoring the stent
phenotype to an inert bare-metal stent. Among patients with
DM, thick-strut BP-DES have been shown to provide compa-
rable long-term clinical outcomes and signiﬁcantly lower rates
of deﬁnite or probable stent thrombosis compared with ﬁrst-
generation thick-strut durable polymer sirolimus-eluting
stents.8 Recently, ultrathin-strut BP-SES demonstrated similar
safety and efﬁcacy outcomes compared with thin-strut DP-
EES at 1-year follow-up in patients with DM,9 but whether
potential differences between BP-SES and DP-EES may
emerge during extended follow-up, when drug elution and
polymer degradation are completed, remains unknown. We
therefore performed a subgroup analysis of patients included
in the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer
Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-
Eluting Stent for Percutaneous Coronary Revascularization)
trial to assess the effect of DM on long-term outcomes in
patients treated with ultrathin-strut BP-SES versus thin-strut
DP-EES.
Methods
Study Design and Study Population
We performed a prespeciﬁed subgroup analysis of patients
with insulin-dependent or noninsulin-dependent DM enrolled
in the BIOSCIENCE trial. Detailed descriptions of the study
rationale, design, inclusion and exclusion criteria, methods,
and data management have been previously reported.10
Brieﬂy, BIOSCIENCE was an investigator-initiated, prospective,
multicenter, single-blind, randomized, noninferiority trial
including patients with stable coronary artery disease or
acute coronary syndrome and minimal exclusion criteria.
Patients with at least one >50% diameter coronary stenosis or
in-stent restenosis in a native coronary vessel or bypass graft
suitable for PCI were randomly allocated in a 1:1 ratio to
treatment with BP-SES or DP-EES. The ﬁnal 5-year results of
the BIOSCIENCE trial were recently reported.11 The study
protocol complied with the Declaration of Helsinki and was
approved by the institutional ethics committees at each
participating site. All enrolled patients provided written
informed consent for participation. The trial is registered with
ClinicalTrials.gov (NCT01443104). The data that support the
ﬁndings of this study are available from the corresponding
author upon reasonable request.
Study Procedures
The BP-SES (Orsiro, Biotronik AG) consists of an ultrathin-strut
(60 lm for stent diameters ≤3.0 mm and 80 lm for stent
diameters >3.0 mm) cobalt-chromium L-605 metallic stent
platform covered by both a permanent silicon-carbide passive
coating that reduces interaction between the metallic stent
surface and the surrounding tissue, and a biodegradable poly-
L-lactic acid polymer active coating that elutes sirolimus at a
reduced dose of 1.4 lg/mm2 stent surface over a 12- to 14-
week period.12 The asymmetrical polymer matrix completely
degrades after 2 years.12 The DP-EES (Xience Prime/
Xpedition, Abbott Vascular) consists of a thin-strut (81 lm) L-
605 cobalt-chromium stent platform coated with a durable
poly-n-butyl-methacrylate and vinylidine ﬂuoride and hexaﬂu-
oropropylene co-polymer that releases everolimus. Eligible
Clinical Perspective
What Is New?
• At 5 years, ultrathin-strut biodegradable polymer sirolimus-
eluting stents provide similar long-term efﬁcacy and safety
outcomes compared with thin-strut durable polymer ever-
olimus-eluting stents in patients with diabetes mellitus
undergoing percutaneous coronary revascularization.
• Despite improvements in evidence-based medical therapy
and recent iterations in drug-eluting stent technology
including ultrathin-strut stent platforms and biodegradable
polymer coatings, patients with diabetes mellitus remain at
increased long-term risk for adverse clinical outcomes after
percutaneous coronary intervention compared with individ-
uals without diabetes mellitus.
What Are the Clinical Implications?
• At long-term follow-up, ultrathin-strut biodegradable poly-
mer sirolimus-eluting stents represent a safe and effective
alternative to thin-strut durable polymer everolimus-eluting
stents for the treatment of patients with diabetes mellitus
undergoing percutaneous coronary revascularization, but
further research is still warranted to determine the optimal
drug-eluting stent therapy in this high-risk patient subgroup.
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patients were randomized using a web-based system and
stratiﬁed according to the study center and to the presence or
absence of ST-segment elevation MI. PCI was performed
according to current guidelines at the time of study enroll-
ment. Unfractionated heparin (5 000 IU or 70–100 IU/kg of
body weight) or bivalirudin, and glycoprotein IIb/IIIa inhibitors
were administrated at the operator’s discretion. Dual
antiplatelet therapy, consisting of acetylsalicylic acid
(>250 mg) combined with clopidogrel (loading dose,
600 mg; maintenance dose, 75 mg QD), prasugrel (loading
dose, 60 mg; maintenance dose, 10 mg QD), or ticagrelor
(loading dose, 180 mg; maintenance dose, 90 mg BID), was
administered before or at the time of PCI and continued for a
recommended period of 12 months.
Deﬁnition
All patients previously diagnosed and treated for insulin-
dependent and noninsulin-dependent DM, as well as patients
with DM under diet control, were considered for the present
analysis. The presence or absence of DM at presentation was
determined by the enrolling physician based on the informa-
tion collected from the patient and medical records.
Study End Points
The primary end point was target lesion failure (TLF), deﬁned
as the composite of cardiac death, target vessel MI, or
clinically indicated target lesion revascularization (TLR), within
5 years. All primary and secondary end point deﬁnitions are
outlined in detail in Data S1. Data collection and monitoring
have been previously described.10 Any adverse event was
independently adjudicated by a clinical events committee
blinded to treatment assignment.
Statistical Analyses
Patients enrolled in the BIOSCIENCE trial and randomly
assigned to treatment with BP-SES or DP-EES were stratiﬁed
according to diabetic status. All analyses were performed in
the intention-to-treat population, consisting of all patients
who underwent randomization, irrespective of the treatment
received. Baseline characteristics of study patients were
presented as frequencies and percentages for categorical
variables and meansSDs for continuous variables. Treat-
ment effects for baseline characteristics were calculated
using unpaired t tests, chi-square tests, or Fisher exact tests,
except when speciﬁed, for per-patient analyses, and general
(continuous variables) or generalized linear mixed models
(counts numbers) accounting for the nonindependence of
lesions within the same patient for per-lesion analyses.
Kaplan-Meier estimates were used to construct survival
curves for time-to-event outcomes that were compared by
means of the log-rank test. All events were censored beyond
1825 days of follow-up. The Mantel-Cox method with 2-sided
P values from log-rank test was used to calculate rate ratios
(RRs) with 95% CIs. Approximate Mantel-Haenszel chi-square
tests for effect modiﬁcation were used to determine the
interaction between diabetic status and randomized stent
type. A P value of 0.05 was considered statistically signiﬁcant.
Stata software (version 14.2, StataCorp) was used for all
statistical analyses.
Results
Between March 1, 2012, and May 31, 2013, 2119 patients
with 3139 lesions were enrolled in the BIOSCIENCE trial. A
total of 1063 patients (257 patients with DM and 806 patients
without DM) were randomly assigned to treatment with BP-
SES and 1056 patients (229 patients with DM and 827
patients without DM) were randomly assigned to treatment
with DP-EES (Figure 1). Among 486 patients (22.9%) with DM,
257 patients with 396 lesions were randomized to treatment
with BP-SES and 229 patients with 331 lesions were allocated
to treatment with DP-EES. Among the remaining 1633 (77.1%)
patients without DM, 806 patients with 1198 lesions were
randomly assigned to treatment with BP-SES and 827 patients
with 1214 lesions were randomized to treatment with DP-EES
(Figure 1). At 5 years, follow-up data were available for 1012
(95.2%) patients treated with BP-SES (240 patients with DM
and 772 patients without DM) and for 1014 (96.0%) patients
treated with DP-EES (221 patients with DM and 793 patients
without DM) (Figure 1).
Baseline clinical characteristics are summarized in
Table 1 and were well balanced between treatment arms
in both patients with DM and patients without DM.
Compared with individuals without DM, patients with DM
were older and had a greater baseline cardiac risk proﬁle,
including a higher prevalence of cardiovascular risk factors
(hypertension, hypercholesterolemia), peripheral artery dis-
ease, chronic renal failure, and history of PCI, coronary
artery bypass graft surgery, or cerebrovascular event. Most
patients with DM (n=345, 71%) were taking oral hypo-
glycemic agents, whereas 161 (33.1%) patients presented
with insulin-dependent DM, including 90 (35.0%) patients
allocated to BP-SES and 71 (31%) patients allocated to DP-
EES. Nearly half of the patients with DM (n=217, 44.7%)
presented with acute coronary syndrome (114 patients
allocated to BP-SES and 103 patients allocated to DP-EES).
At baseline, cardiac medications, including antiplatelet
agents, statins, angiotensin-converting enzyme inhibitors,
and b-blockers, were more commonly prescribed to patients
with DM than patients without DM. Notably, 114 (23.6%)
patients with DM and 282 (17.5%) individuals without DM
DOI: 10.1161/JAHA.119.013607 Journal of the American Heart Association 3
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were on dual antiplatelet therapy at 5-year follow-up.
Baseline angiographic and procedural characteristics are
summarized in Table 2 and were similar between both
treatment arms with respect to target lesion characteristics,
including target vessel location and number of lesions
treated.
At 5 years, TLF occurred in 131 patients (cumulative
incidence, 28.5%) with DM and 256 patients (16.8%)
without DM (RR, 1.87; 95% CI, 1.51–2.31 [P<0.001])
(Table 3). The 5-year cumulative incidence rates of cardiac
death (12.3% versus 6.8%; RR, 1.95 [95% CI, 1.41–2.71]),
target vessel MI (11.2% versus 5.4%; RR, 2.10 [95% CI,
1.47–2.98]), and clinically indicated TLR (16.4% versus
8.6%; RR, 2.01 [95 CI, 1.51–2.69]) were signiﬁcantly higher
among patients with DM compared with individuals without
DM (P<0.001 for all) (Table 3). The cumulative 5-year rates
of deﬁnite stent thrombosis were signiﬁcantly higher among
patients with DM compared with individuals without DM
(2.8% versus 1.3%; RR, 2.10 [95% CI, 1.03–4.28]; P=0.04)
(Table 3).
At 5 years of follow-up, the primary composite end point of
TLF occurred in 74 patients (31.0%) treated with BP-SES and
57 patients (25.8%) treated with DP-EES (RR 1.23; 95% CI
0.87–1.73 [P=0.24]) among patients with DM, and in 124
patients (16.8%) treated with BP-SES and 132 patients
(16.8%) treated with DP-EES (RR, 0.98; 95% CI, 0.77–1.26
[P=0.90]) in individuals without DM (P for interaction=0.31)
(Table 3, Figure 2). Cumulative incidence rates of cardiac
death (14.9% versus 9.5%; RR, 1.56 [95% CI, 0.91–2.69];
P=0.10), target vessel MI (11.4% versus 11.0%; RR, 1.07 [95%
CI, 0.61–1.89]; P=0.81), and clinically indicated TLR (16.9%
versus 15.8%; RR, 1.10 [95% CI, 0.69–1.76]; P=0.68) were
comparable between patients with DM treated with BP-SES or
DP-EES (Table 3, Figure 2). The cumulative incidence of
deﬁnite stent thrombosis at 5 years was 3.0% and 2.5% in
patients with DM allocated to treatment with BP-SES and DP-
EES, respectively (RR, 1.33; 95% CI, 0.42–4.24 [P=0.63]), and
1.2% and 1.4% in individuals without DM allocated to
treatment with BP-SES and DP-EES, respectively (RR, 0.85;
95% CI, 0.35–2.06 [P=0.73; P for interaction=0.55]) (Table 3).
Figure 1. Patient ﬂow according to CONSORT statement. BMS indicates bare-metal stents; BP-SES, biodegradable polymer sirolimus-eluting
stents; CABG, coronary artery bypass grafting; DP-EES, durable polymer everolimus-eluting stents; PCI, percutaneous coronary intervention.
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Table 1. Baseline Clinical Characteristics
Patients With DM Patients Without DM
All BP-SES DP-EES All BP-SES DP-EES
Patients, No. N=486 n=257 n=229 N=1633 n=806 n=827
Age, meanSD, y 67.910.5 68.610.7 67.110.4 65.511.7 65.311.8 65.611.6
Male sex, No. (%) 370 (76.1) 198 (77.0) 172 (75.1) 1262 (77.3) 620 (76.9) 642 (77.6)
Body mass index, meanSD, kg/m2 25.54.8 25.84.6 29.25.0 27.14.3 27.14.3 27.14.3
DM, No. (%)
Orally treated 345 (71.0) 179 (69.6) 166 (72.5) NA NA NA
Insulin-treated 161 (33.1) 90 (35.0) 71 (31.0) NA NA NA
Hypertension, No. (%) 409 (84.3) 221 (86.0) 188 (82.5) 1025 (62.8) 507 (63.0) 518 (62.6)
Hypercholesterolemia, No. (%) 361 (74.3) 189 (73.5) 172 (75.1) 1067 (65.4) 523 (65.0) 544 (65.8)
Current smoker, No. (%) 109 (22.4) 56 (17.8) 53 (23.1) 500 (30.7) 253 (31.4) 247 (29.9)
Family history of CAD, No. (%) 127 (26.2) 62 (20.1) 65 (28.5) 460 (28.3) 230 (28.7) 230 (27.8)
Previous MI, No. (%) 123 (25.3) 64 (24.9) 59 (25.8) 304 (18.6) 159 (19.7) 145 (17.5)
Previous PCI, No. (%) 187 (38.5) 103 (40.1) 84 (36.7) 430 (26.3) 222 (27.5) 208 (25.2)
Previous CABG, No. (%) 84 (17.3) 55 (17.4) 29 (12.7) 127 (7.8) 58 (7.2) 69 (8.3)
Atrial fibrillation, No. (%) 42 (8.6) 23 (8.9) 19 (8.3) 121 (7.4) 60 (7.4) 61 (7.4)
Previous stroke or TIA, No. (%) 30 (6.2) 13 (5.1) 17 (7.4) 66 (4.0) 26 (3.2) 40 (4.8)
Peripheral vascular disease, No. (%) 71 (14.6) 42 (16.3) 29 (12.7) 105 (6.4) 53 (6.6) 52 (6.3)
Renal failure (GFR <60 mL/min), No. (%) 105 (23.0)* 58 (24.5)† 47 (17.4)‡ 177 (11.4)§ 93 (12.1)k 84 (10.8)¶
Left ventricular ejection fraction, meanSD, % 54.413.7# 53.613.6** 55.113.9†† 56.211.9‡‡ 56.311.6§§ 56.112.2kk
Clinical presentation, No. (%)
Unstable angina 34 (7.0) 16 (6.2) 18 (7.9) 118 (7.2) 62 (7.7) 56 (6.8)
NSTEMI 126 (25.9) 68 (26.5) 58 (25.3) 445 (27.3) 219 (27.2) 226 (27.3)
STEMI 57 (11.7) 30 (11.7) 27 (11.8) 351 (21.5) 182 (22.6) 169 (20.4)
Stable angina 192 (39.5) 103 (40.1) 89 (38.9) 569 (34.9) 268 (33.3) 301 (36.4)
Silent ischemia 77 (15.8) 40 (15.6) 37 (16.2) 149 (9.1) 74 (9.2) 75 (9.1)
Baseline medications, No. (%)
Aspirin 343 (70.9) 179 (70.2) 164 (71.6) 895 (55.7)¶¶ 432 (54.4)## 463 (56.9)***
Clopidogrel 95 (19.6) 43 (16.9) 52 (22.7) 193 (12.0)¶¶ 86 (10.8)## 107 (13.2)***
Prasugrel 20 (4.1) 11 (4.3) 9 (3.9) 60 (3.7)¶¶ 32 (4.0)## 28 (3.4)***
Ticagrelor 22 (4.5) 9 (3.5) 13 (5.7) 67 (4.2)¶¶ 29 (3.7)## 38 (4.7)***
Any dual antiplatelet therapy 114 (23.6) 54 (21.2) 60 (26.2) 282 (17.5)¶¶ 127 (16.0)## 155 (19.1)***
Vitamin K oral anticoagulant 42 (8.7) 23 (9.0) 19 (8.3) 94 (5.8)¶¶ 50 (6.3)## 44 (5.4)***
Nonvitamin K oral anticoagulant 2 (0.4) 2 (0.8) 0 (0) 4 (0.2)¶¶ 1 (0.1)## 3 (0.4)***
Any anticoagulant therapy 44 (9.1) 25 (9.8) 19 (8.3) 98 (6.1)¶¶ 51 (6.4)## 47 (5.8)***
Statins 336 (69.6) 178 (69.8) 158 (69.3) 789 (49.1)¶¶ 384 (48.4)## 405 (49.8)***
ACE inhibitors or ARBs 182 (37.7) 100 (39.2) 82 (36.0) 366 (22.8)¶¶ 171 (21.6)## 195 (24.0)***
b-Blockers 274 (56.7) 153 (60.0) 121 (53.1) 695 (43.3)¶¶ 343 (43.3)## 352 (43.3)***
P values from Fisher exact tests and unpaired t tests, respectively. ACE indicates angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; BP-SES, biodegradable polymer
sirolimus-eluting stents; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DM, diabetes mellitus; DP-EES, durable polymer everolimus-eluting stents; GFR, glomerular
ﬁltration rate; MI, myocardial infarction; NA, not applicable; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment–
elevation myocardial infarction; TIA, transient ischemic attack.
*n=457; †n=237; ‡n=220; §n=1546; kn=771; ¶n=775; #n=377; **n=199; ††n=178; ‡‡n=1320; §§n=653; kkn=667; ¶¶n=1607; ##n=794; ***n=813.
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Discussion
In a prespeciﬁed subgroup analysis of the large-scale,
multicenter, randomized BIOSCIENCE trial, BP-SES provided
similar long-term clinical beneﬁt compared with DP-EES
regarding the composite of TLF in unselected patients with
DM undergoing PCI. To our knowledge, the present study is
the ﬁrst to assess the effect of BP-DES compared with
contemporary durable biocompatible polymer-based DES
among patients with DM throughout 5 years.
Contemporary second-generation DES have reached a high
level of safety and efﬁcacy, and the importance of stent-related
relative to disease-related events has decreased, thereby
underscoring the paramount importance of secondary preven-
tion of the underlying disease process. The present analysis
conﬁrms that, despite signiﬁcant improvements in evidence-
based medical management and iterative developments in DES
technology, patients with DM remain at increased risk for TLF,
mainly driven by higher rates of TLR, following PCI with newer-
generation DES compared with individuals without DM,
irrespective of the underlying coronary artery disease com-
plexity.13 Diabetic status affects short- and long-term clinical
outcomes after PCI through multiple mechanisms, including
disturbances that accelerate atherosclerosis progression,
patient comorbidities, and anatomical factors that increase
coronary artery disease complexity (eg, multivessel disease,
diffuse lesions, high grades of calciﬁcation and tortuosity,
higher incidence of left main disease, bifurcation lesions and
chronic total occlusions, smaller reference vessel diameter,
longer lesions, and greater plaque burden).14,15 In addition, the
proinﬂammatory milieu of DM enhances the vasculo-prolif-
erative response to stent-mediated arterial injury.16 Thus, DM
Rate Ratio (95% CI) comparing randomized stents:
  Diabetics        RR (95%CI)=1.23 (0.87-1.73), P=0.244
  Non-Diabetics RR (95%CI)=0.98 (0.77-1.26), P=0.901
  interaction P=0.307
0
5
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)
806 742 687 651 620 587Non: BP-SES
827 762 727 693 663 642Non: DP-EES
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Years since index procedure
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Figure 2. Time to event curves for the composite end point target lesion failure and individual components of the primary end point up to
5 years in patients with diabetes mellitus (DM) vs patients without DM. A, Target lesion failure; B, cardiac death; C, target vessel (TV) myocardial
infarction; D, clinically driven target lesion revascularization (TLR). Blue lines indicate biodegradable polymer sirolimus-eluting stent, patients
with DM subgroup (BP-SES, DM); red lines indicate durable polymer everolimus-eluting stent, patients with DM subgroup (DP-EES, DM); grey
lines indicate biodegradable polymer sirolimus-eluting stent, patients without DM subgroup (BP-SES, Non); and orange lines indicate durable
polymer everolimus-eluting stent, patients without DM subgroup (DP-EES, Non). RR indicates rate ratio.
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is associated with both a higher rate of recurrent ischemic
events related to atherosclerotic disease progression and
worse clinical outcomes related to stent failure following PCI.14
In the present analysis, though optimal secondary prevention
medical therapy was more commonly prescribed in patients
with DM than in individuals without DM, all-comer patients with
DM treated with newer-generation biocompatible DES experi-
enced higher rates of TLF, cardiac death, target vessel MI,
clinically indicated TLR and deﬁnite stent thrombosis at
5 years of follow-up compared with patients without DM. TLF
accounted for approximately two thirds of the patient-oriented
clinical outcome, a composite of death, MI, or any repeat
revascularization, among both patients with and those without
DM, and the proportion of target lesion-related events to
patient-related events were comparable in both the DM and
non-DM groups. Of note, even with the latest-generation
biocompatible DES, patients with DM remain at higher risk of
long-term deﬁnite or probable stent thrombosis compared with
individuals without DM.
The choice of optimal DES therapy for patients with DM
undergoing PCI remains an unresolved issue.17–19 Newer-
generation DES with thinner-strut cobalt- or platinum-chro-
mium platforms, more biocompatible permanent polymer
coatings and alternative antiproliferative drugs were shown
to signiﬁcantly reduce the risk of repeat revascularization
without compromising safety outcomes, including stent
thrombosis, compared with bare-metal stents and early-
generation thick-strut permanent polymer-based DES in both
patients with DM5 and patients without DM.20 Available
evidence supports the use of thin-strut DP-EES in patients with
DM undergoing PCI. In a large-scale meta-analysis,5 thin-strut
DP-EES were shown to provide the most favorable efﬁcacy and
safety proﬁle in patients with DM compared with early-
generation thick-strut DP-DES and thin-strut durable polymer
zotarolimus-eluting stents with a 2-, 3-, 4-, and 9-fold risk
reduction in target vessel revascularization, TLR, MI, and
deﬁnite or probable stent thrombosis, respectively. Similarly,
in a recent meta-analysis of 18 trials including 17 000 patient-
years of follow-up,21 thin-strut DP-EES were associated with
signiﬁcant reductions by 18% in major adverse cardiovascular
events, 43% in MI, and 46% in stent thrombosis among patients
with DM, whereas thin-strut durable polymer zotarolimus-
eluting stents were associated with an 89% increased risk of
TLR, compared with early-generation thick-strut DP-DES.
Furthermore, thin-strut DP-EES demonstrated a trend towards
lower TLR and target vessel revascularization rates and a
greater clinical beneﬁt over early-generation thick-strut DP-
DES with regards to major adverse cardiovascular events and
stent thrombosis among insulin-dependent individuals with
DM.21 However, these ﬁndings are only hypothesis-generating
because of the limited available outcome data on zotarolimus-
eluting stents in the diabetic population.
BP-DES, with controlled drug release followed by subse-
quent degradation of the polymer coating, were developed to
overcome the chronic inﬂammatory stimulus and hypersen-
sitivity reactions elicited by durable polymer coatings that
result in delayed vascular healing.6 Conceptually, the
biodegradable polymer-based DES technology represents
an attractive treatment option for patients with DM and
avoids persistent arterial injury through polymer biodegra-
dation, thereby potentially reducing persisting late adverse
clinical event rates associated with newer-generation DP-
DES.7 Recently, BP-SES demonstrated comparable clinical
outcomes with regards to TLF and deﬁnite or probable stent
thrombosis compared with thin-strut DP-EES at 1-year
follow-up among patients with DM.9 However, longer-term
safety and efﬁcacy data after percutaneous revascularization
with available BP-DES in patients with DM are limited and
whether potential differences between BP-DES and DP-DES
may emerge at extended follow-up remains unknown. In a
patient-level pooled meta-analysis,8 biodegradable polymer
biolimus-eluting stents with a thick-strut stainless steel
platform were associated with comparable clinical outcomes
compared with ﬁrst-generation thick-strut durable polymer
sirolimus-eluting stents at 4 years, but demonstrated a more
favorable safety proﬁle with signiﬁcantly lower deﬁnite or
probable stent thrombosis rates, driven by signiﬁcantly lower
rates of very late stent thrombosis among patients treated
with BP-DES. In a recent predeﬁned subgroup analysis of the
NOBORI 2 multicenter registry including 888 patients with
DM treated with thick-strut biodegradable polymer biolimus-
eluting stents,22 TLF rates were signiﬁcantly higher in
patients with DM than in individuals without DM, and in
insulin-dependent than in noninsulin-dependent patients with
DM, at 5-year follow-up. Notwithstanding, deﬁnite and
probable stent thrombosis rates at 5 years were similar
among patients with DM versus individuals without DM, or
insulin-dependent versus noninsulin-dependent patients with
DM with extremely low very late stent thrombosis events in
both patients with DM and insulin-dependent DM.22 The
present analysis extends previous knowledge by providing
long-term randomized outcome data after PCI with newer-
generation ultrathin-strut BP-DES in patients with DM. At 5-
year follow-up, we found that ultrathin-strut BP-SES were
associated with similar clinical outcomes, including stent
thrombosis, compared with thin-strut DP-EES among
patients with DM, without signiﬁcant interaction between
diabetic status and treatment effect of BP-SES and DP-EES.
These ﬁndings are consistent with the long-term results
reported in the overall study population11 and suggest that
ultrathin-strut BP-DES may represent a valuable treatment
option even in the high-risk DM subgroup with similar long-
term efﬁcacy and safety outcomes compared with thin-strut
durable polymer-based DES.
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In addition to the polymer coating characteristics, stent
strut thickness is another major component of DES design
that potentially affects clinical outcomes after PCI in patients
with DM. A recent large-scale study-level meta-analysis
demonstrated lower rates of TLF with ultrathin-strut DES
compared with contemporary-generation thin-strut DES.23
Available evidence on the effect of ultrathin-strut DES on
clinical outcomes in patients with DM is limited. In a subgroup
analysis of the SORT OUT VII (Scandinavian Organization for
Randomized Trials With Clinical Outcome) trial,24 no signiﬁ-
cant differences with regards to rates of TLF, cardiac death,
MI, and TLR were observed among patients with DM allocated
to ultrathin-strut BP-SES or thick-strut biodegradable polymer
biolimus-eluting stents at 2-year follow-up, despite numeri-
cally lower rates of deﬁnite or probable stent thrombosis
among patients with DM treated with BP-SES. However, these
ﬁndings warrant conﬁrmation from dedicated and adequately
powered clinical trials comparing newer-generation ultrathin-
strut and thin-strut DES in the diabetic population.
Study Limitations
The present analysis must be interpreted in view of several
limitations. First, as per the design of the main trial,
randomization was not stratiﬁed according to diabetic status.
Second, diabetic status was assessed based on the patient
clinical history at admission, and patients with newly
diagnosed DM during hospitalization or follow-up were not
included. Furthermore, levels of glycohemoglobin were not
available for the entire diabetic population. Third, although
prespeciﬁed, this subgroup analysis was not powered for the
reported end points and the results can only be interpreted as
hypothesis-generating. Fourth, we did not stratify the present
analysis according to insulin-dependent or noninsulin-depen-
dent DM because of the limited total number of patients with
DM included in the trial.
Conclusions
In the prespeciﬁed subgroup analysis of the BIOSCIENCE trial,
long-term clinical outcomes in patients with DM treated with
BP-SES or DP-EES were comparable throughout 5 years.
Despite iterative developments in DES technology, patients
with DM remain at increased long-term TLF risk compared
with individuals without DM.
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 Data S1. 
 
STUDY ENDPOINTS DEFINITIONS 
 
1. Cardiac death 
Cardiac death was considered any death due to proximate cardiac cause, death related to 
the procedure, unwitnessed death, or death of unknown etiology. 
2. Myocardial infarction 
Myocardial infarction (MI) was defined as Q-wave and non-Q-wave according to the 
Minnesota code manual electrocardiographic criteria (1). 
Spontaneous MI was considered as any creatinine kinase (CK)-MB fraction or troponin 
level elevation above the upper limit of normal (ULN) and fall associated with ischemic 
symptoms, new pathological Q waves, new electrocardiographic abnormalities suggestive 
of myocardial ischemia, and/or pathological evidence of acute MI (2). 
Periprocedural MI was defined as an elevation of total CK >2 times ULN in the presence 
of a confirming cardiac biomarker obtained after the procedure. Periprocedural MI in the 
setting of evolving MI was recorded in case of recurrent chest pain >20 minutes duration 
(or new ECG changes consistent with MI) in combination with a >50% elevation of peak 
CK (or CK-MB in the absence of CK) level above the previous level measured within 24 
hours after the event (3). 
3. Target lesion revascularization 
Target lesion revascularization (TLR) was defined as any repeat percutaneous or surgical 
intervention due to a coronary stenosis or occlusion within the stent or within the 5 mm 
borders proximal or distal to the stent. 
4. Target vessel revascularization 
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 Target vessel revascularization (TVR) was considered as any revascularization within the 
entire coronary vessel proximal or distal to a target lesion, including upstream and 
downstream side branches and the target lesion itself. 
5. Clinically-indicated revascularization 
Clinically-indicated revascularization was defined as any revascularization of the target 
lesion or target vessel associated with either signs or symptoms of myocardial ischemia 
and a 50% diameter coronary stenosis, or a 70% diameter coronary stenosis 
irrespective of the presence of signs or symptoms of myocardial ischemia. 
6. Stent thrombosis 
Stent thrombosis was defined according to the Academic Research Consortium criteria 
(4). 
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